139 related articles for article (PubMed ID: 36441548)
21. Genomic profiling of breast cancer in African-American women using MammaPrint.
Nunes RA; Wray L; Mete M; Herbolsheimer P; Smith KL; Bijelic L; Boisvert ME; Swain SM
Breast Cancer Res Treat; 2016 Oct; 159(3):481-8. PubMed ID: 27568021
[TBL] [Abstract][Full Text] [Related]
22. Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
Turashvili G; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
BMC Cancer; 2018 Jan; 18(1):42. PubMed ID: 29304773
[TBL] [Abstract][Full Text] [Related]
23. Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.
Mutonga M; Speedy S; Rademaker A; Liu D; Uthe R; Jain S; Gradishar WJ; Flaum L; Santa-Maria CA
Breast Cancer Res Treat; 2019 Jul; 176(1):95-100. PubMed ID: 30977026
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
Pestalozzi BC; Tausch C; Dedes KJ; Rochlitz C; Zimmermann S; von Moos R; Winterhalder R; Ruhstaller T; Mueller A; Buser K; Borner M; Novak U; Nussbaum CU; Seifert B; Bigler M; Bize V; Vilei SB; Rageth C; Aebi S;
BMC Cancer; 2017 Apr; 17(1):265. PubMed ID: 28407750
[TBL] [Abstract][Full Text] [Related]
25. Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.
Shieh Y; Scott CG; Jensen MR; Norman AD; Bertrand KA; Pankratz VS; Brandt KR; Visscher DW; Shepherd JA; Tamimi RM; Vachon CM; Kerlikowske K
Breast Cancer Res; 2019 Apr; 21(1):48. PubMed ID: 30944014
[TBL] [Abstract][Full Text] [Related]
26. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
27. Association of 21-gene recurrence score and locoregional recurrence in early breast cancer patients.
Zeng Y; Gao W; Chen X; Shen K
Cancer Biomark; 2022; 35(1):111-118. PubMed ID: 35912728
[TBL] [Abstract][Full Text] [Related]
28. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
[TBL] [Abstract][Full Text] [Related]
29. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
30. Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention.
Wang F; Liu L; Cui S; Tian F; Fan Z; Geng C; Cao X; Yang Z; Wang X; Liang H; Wang S; Jiang H; Duan X; Wang H; Li G; Wang Q; Zhang J; Jin F; Tang J; Li L; Zhu S; Zuo W; Ma Z; Zhou F; Yu L; Xiang Y; Li L; Shen S; Yu Z
Oncologist; 2017 Dec; 22(12):1431-1443. PubMed ID: 28912152
[TBL] [Abstract][Full Text] [Related]
31. Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer.
Tamirisa N; Lin H; Shen Y; Shaitelman SF; Sri Karuturi M; Giordano SH; Babiera G; Bedrosian I
JAMA Oncol; 2020 Oct; 6(10):1548-1554. PubMed ID: 32672820
[TBL] [Abstract][Full Text] [Related]
32. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
[TBL] [Abstract][Full Text] [Related]
33. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Ibraheem AF; Press DJ; Olopade OI; Huo D
Cancer; 2019 Jan; 125(2):213-222. PubMed ID: 30387876
[TBL] [Abstract][Full Text] [Related]
34. Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay.
Muniz J; Kidwell KM; Henry NL
Breast Cancer Res Treat; 2016 Jun; 157(3):597-603. PubMed ID: 27271766
[TBL] [Abstract][Full Text] [Related]
35. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.
Mittendorf EA; Vila J; Tucker SL; Chavez-MacGregor M; Smith BD; Symmans WF; Sahin AA; Hortobagyi GN; Hunt KK
JAMA Oncol; 2016 Jul; 2(7):929-36. PubMed ID: 26986538
[TBL] [Abstract][Full Text] [Related]
36. Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States.
Altman AM; Kizy S; Yuan J; Denbo JW; Jensen EH; Hui JYC; Tuttle TM; Marmor S
Ann Surg Oncol; 2018 Aug; 25(8):2296-2302. PubMed ID: 29907942
[TBL] [Abstract][Full Text] [Related]
37. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
Ritte R; Lukanova A; Berrino F; Dossus L; Tjønneland A; Olsen A; Overvad TF; Overvad K; Clavel-Chapelon F; Fournier A; Fagherazzi G; Rohrmann S; Teucher B; Boeing H; Aleksandrova K; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Sieri S; Panico S; Tumino R; Vineis P; Quirós JR; Buckland G; Sánchez MJ; Amiano P; Chirlaque MD; Ardanaz E; Sund M; Lenner P; Bueno-de-Mesquita B; van Gils CH; Peeters PH; Krum-Hansen S; Gram IT; Lund E; Khaw KT; Wareham N; Allen NE; Key TJ; Romieu I; Rinaldi S; Siddiq A; Cox D; Riboli E; Kaaks R
Breast Cancer Res; 2012 May; 14(3):R76. PubMed ID: 22583394
[TBL] [Abstract][Full Text] [Related]
38. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.
Wolf I; Ben-Baruch N; Shapira-Frommer R; Rizel S; Goldberg H; Yaal-Hahoshen N; Klein B; Geffen DB; Kaufman B
Cancer; 2008 Feb; 112(4):731-6. PubMed ID: 18076012
[TBL] [Abstract][Full Text] [Related]
39. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
[TBL] [Abstract][Full Text] [Related]
40. 21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients.
Zhu Y; Wang T; Tong Y; Chen X; Shen K
Front Endocrinol (Lausanne); 2021; 12():725161. PubMed ID: 34456877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]